PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn How the Study Medicine Called [14C]PF-07054894 is Processed by the Body

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: PF-07054894

First Posted Date: 2025-06-06

Last Posted Date: 2025-06-06

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT07009353

A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults

Phase 1

Not yet recruiting

Conditions: Healthy

Interventions: Drug: PF-07985631
Drug: Placebo

First Posted Date: 2025-05-29

Last Posted Date: 2025-05-29

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT06994897

A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

Phase 1

Recruiting

Conditions: Acute Treatment of Migraine

Interventions: Drug: Zavegepant

First Posted Date: 2025-05-29

Last Posted Date: 2025-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06995729

Locations: 🇺🇸
Velocity Clinical Research, Washington DC, Washington, District of Columbia, United States
🇺🇸
Central States Research, Tulsa, Oklahoma, United States
🇺🇸
Wasatch Clinical Research, LLC, Salt Lake City, Utah, United States

and more 2 locations

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Phase 2

Not yet recruiting

Conditions: Heart Failure

Interventions: Drug: Placebo
Drug: Low Dose PF-07328948
Drug: Medium Dose PF-07328948
Drug: High Dose PF-07328948

First Posted Date: 2025-05-27

Last Posted Date: 2025-05-27

Lead Sponsor: Pfizer

Target Recruit Count: 620

Registration Number: NCT06991257

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Phase 2

Not yet recruiting

Conditions: Cachexia
Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: ponsegromab
Drug: placebo

First Posted Date: 2025-05-25

Last Posted Date: 2025-05-25

Lead Sponsor: Pfizer

Target Recruit Count: 982

Registration Number: NCT06989437

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

Phase 2

Recruiting

Conditions: Asthma

Interventions: Drug: PF-07275315
Other: Placebo

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-18

Lead Sponsor: Pfizer

Target Recruit Count: 252

Registration Number: NCT06977581

Locations: 🇺🇸
Velocity Clinical Research, Mobile, Mobile, Alabama, United States
🇺🇸
Clinical Research of Rock Hill, Rock Hill, South Carolina, United States
🇺🇸
Allergy and Asthma Associates of Santa Clara Valley Research Center, San Jose, California, United States

and more 4 locations

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

Phase 1

Not yet recruiting

Conditions: Carcinoma, Non Small Cell Lung
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Carcinoma, Pancreatic Ductal
Malignant Melanoma

Interventions: Drug: PF-08046037
Drug: sasanlimab

First Posted Date: 2025-05-16

Last Posted Date: 2025-05-16

Lead Sponsor: Pfizer

Target Recruit Count: 399

Registration Number: NCT06974734

Locations: 🇺🇸
START Midwest, Grand Rapids, Michigan, United States

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Phase 1

Not yet recruiting

Conditions: Breast Cancer
Breast Neoplasms

Interventions: Drug: Disitamab vedotin

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-11

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT06966453

A Study to Learn How Different Amounts of the Study Medicine Called PF-07999415 Are Tolerated and Act in the Body in Healthy Adults

Phase 1

Not yet recruiting

Conditions: Healthy Adults

Interventions: Biological: PF-07999415
Drug: Placebo

First Posted Date: 2025-05-11

Last Posted Date: 2025-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT06965465

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

Not yet recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: Ibrance

First Posted Date: 2025-05-08

Last Posted Date: 2025-05-08

Lead Sponsor: Pfizer

Target Recruit Count: 1000

Registration Number: NCT06962969

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy